CPT code 23065 denotes a superficial soft tissue biopsy of the shoulder, used to obtain a tissue specimen from a small subcutaneous or surface-level lesion for pathological examination. This procedure is clinically important because it establishes diagnoses such as infection, inflammatory disease, or cancer, guiding subsequent treatment decisions and care pathways. Nationally, accurate coding and documentation for this procedure affect clinical tracking, quality measurement, and claims adjudication across payers.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for the procedure, typical sites of service, and the common payer landscape. The publication outlines benchmarks and coverage considerations, summarizes relevant coding nuances for claims submissions, and highlights areas where policy updates or payer-specific rules commonly influence authorization and reimbursement workflows.

This overview is intended for clinicians, coding professionals, and revenue cycle staff seeking a clear reference for CPT code 23065, its clinical purpose, and the payer environment that typically governs coverage and processing of claims for superficial shoulder soft tissue biopsies.